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Introduction 
Carcinoma remains the major cause of  morbidity and mortality 
all over the world and it is the leading cause of  death with its 
relative position varies with age and sex. Oral and oropharyngeal 
carcinoma are the sixth most common cancers in the world and 
oral cavity squamous cell carcinoma (OCSCC) constitutes 90 % 
of  all cases of  oropharyngeal cancer [1]. 
The treatment of  OCSCC involves chemotherapy with or with-
out surgical resection or adjuvant radiotherapy. Despite of  recent 
advances in diagnosis and treatment, oral cancers have significant 
impact on patient’s Health Related Quality of  Life (HRQOL) due 
to disfigurement caused by not only the disease itself  but also due 
to adverse reactions caused by treatment [2].
So therapeutic success in management of  OCSCC not only 
should be measured on the basis of  a patient’s survival, absence 
of  recurrence or metastasis but also should be based on the pa-
tient’s overall quality of  life, as increased survival is not necessarily 
associated with improvement in HRQOL.
According to the WHO, HRQOL has been defined as “an indi-
vidual’s perception of  their position in life in the context of  the 
culture and value systems in which they live and in relation to 
their goals, standards and concerns. It is a broad ranging concept 
affected in a complex way by the person’s physical health, psycho-
Abstract
Objective: To evaluate impact of  chemotherapy on Health Related Quality of  Life (HRQOL) in patients of  oral cavity 
squamous cell carcinoma (OCSCC) by analysis of  two different treatments named Concurrent Chemo - Radiation (CTRT) 
and Neo-Adjuvant Chemotherapy (NACT). 
Study Design and Instrument: Prospective longitudinal study by evaluation HRQOL by general quality of  life (QLQ-
C30) and head & neck specific (QLQ-H&N35) questionnaires of  the European Organization for Research and Treatment 
of  Cancer.
Setting: Tertiary care teaching hospital of  India.
Participants and Methodology: Patients with histopathologically proven OCSCC were evaluated before starting chemo-
therapy, after completion of  each cycle and one month after completion of  full course of  chemotherapy. Sequential changes 
of  HRQOL scorings were statistically analyzed by repeated measures ANOVA (P < 0.05) and changes in HRQOL score 
between CTRT and NACT groups were measured by unpaired t-test (P < 0.05).
Results: As compared to baseline, in both the group there was significant deterioration in HRQOL due to development of  
sticky saliva, coughing, feeling of  illness, requirement of  nutritional supplements, social functioning and need of  painkill-
ers. As compared to baseline, deterioration of  global health status, development of  dryness of  mouth, sticky saliva, sense 
problem and trouble with social eating were more significant in CTRT group compared to NACT group, which persisted 
even at one month follow up (P<0.05).
Conclusion: This study has shown that in patients of  oral cavity squamous cell carcinoma, overall baseline HRQOL re-
mained poor, which further deteriorated more in patients receiving CTRT as compared to that of  NACT group.
Abbreviations: Concurrent Chemo - Radiation (CTRT); Health Related Quality of  Life (HRQOL); European Organiza-
tion for Research and Treatment of  Cancer (EORTC); Neo-Adjuvant Chemotherapy (NACT); Oral Cavity Squamous Cell 
Carcinoma (OCSCC).
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social state, level of  independence, social relationships, and their 
relationships to salient features of  their environment” [3].
In developed countries HRQOL measurement is an essential tool 
for assessment of  outcome cancer treatment, but in developing 
countries like India, it is still in the infancy phase at present [4].
In India, oral cancer represents a major health problem, constitut-
ing up to 40% of  all cancers and is the most prevalent cancer in 
males and the third most prevalent cancer in females. In spite of  
such heavy burden of  disease, no such type of  study has yet been 
carried out in patients of  OCSCC in India [5, 6].
The European Organization for Research and Treatment (EO-
RTC) introduced Quality of  Life Questionnaire 30-QLQ-C30 that 
evaluates general aspects of  Quality of  Life (QOL) associated 
with various tumors. Another portion of  questionnaire named 
QLQ-H&N35 contains special questions for patients with head 
and neck tumors. This questionnaire has gained worldwide ac-
ceptance, validation and has been translated into different lan-
guages [7].
So, in the current study, to evaluate impact of  treatment on pa-
tients' HRQOL, comparative analysis of  the effects of  two dif-
ferent treatments named Concurrent Chemo - Radiation (CTRT) 
and Neo-Adjuvant Chemotherapy (NACT) on HRQOL was 
done using EORTC given disease specific questionnaires on In-
dian patients suffering from oral cavity squamous cell carcinoma.
Methodology
Ethical Clearance
The present study was carried out after obtaining permission of  
local Scientific and Ethical Review Committee (SERC) of  a ter-
tiary care teaching hospital of  India and ethical principles of  bio-
medical research were followed throughout this study.
Study Participants
All newly diagnosed patients of  histopathologically proven cases 
of  OCSCC, who were to receive chemotherapy and agreed to par-
ticipate in the study at tertiary care teaching hospital of  Western 
India.
Inclusion Criteria: All newly diagnosed patients who were to 
receive chemotherapy with or without radiation therapy for his-
topathologically proven OCSCC, attending the outpatient depart-
ment of  radiotherapy unit of  tertiary care teaching hospital of  
India, were enrolled in this study.
Patients with age above 18 years, who agreed to give informed-
written consent to participate in the study voluntarily and who 
were able to communicate with any one of  the Indian languages 
of  study instrument, were included in the study.
Exclusion criteria: Following patients were excluded from this 
study: (1) unwillingness to participate the study (2) taking treat-
ment at other centres (3) diagnosed case of  psychiatric illness or 
cognitive impairment (4) pregnant or nursing mother (5) suffering 
from terminal illness.
Sample Size
In India, oral cavity cancer constitutes 29.54% among all malig-
nant biopsies and 95% oral cavity carcinoma with squamous cell 
type. Considering previous records of  radiotherapy department, 
average 15-20 new patients of  OCSCC were receiving chemo-
therapy every month, after using this information for calculating 
sample size at 5% confidence interval with 95% confidence level, 
total estimated minimum sample size for this study was 30.
Treatment protocol
The standard treatment for patients with OCSCC is Concur-
rent Chemo radiation -CTRT followed by definitive surgery [8, 
9], while NACT is either given with the intent of  achieving: (1) 
surgical resection for extensive soft tissue disease, oropharyngeal 
involvement, extensive disease with cartilage erosion or (2) or-
gan preservation for bulky disease with inner cartilage erosion, 
exolaryngeal disease without cartilage erosion or large N3 nodes 
[10-13, 16].
In CTRT group, patients were treated with 25-30 fractions of  50 
- 60 Gray/day External Beam Radiotherapy for 5-6 weeks, using 
reducing fields at site of  OCSCC with weekly chemotherapy as a 
radiation sensitizer. For chemotherapy patients were treated with 
prophylactic Palonosetron, Dexamethasone, Pheniremine Maleate, Man-
nitol and Hydration with 500 ml Dextrose Noraml Saline (DNS), 5% 
Dextrose & Ringger’s Lactate (RL), followed by Cisplatin 12 mg/m2 and 
5-flurouracil (5 FU) 600 mg/m2  every week for six cycles. Overall event 
based - HRQOL evaluation of  patients of  OCSCC was carried 
out before starting first cycle of  chemotherapy (C0), and patients 
were again evaluated every week after completion of  each cycle 
of  chemotherapy at the end of  C1,C2,C3,C4,C5,C6 [14]. The last 
evaluation of  HRQOL was done one month after completion of  
the last cycle of  chemotherapy (i.e. C7).
In NACT group, patients were treated with Palonosetron, Dexameth-
asone, Pheniremine Maleate, Mannitol and Hydration with 500 ml DNS, 
5% Dextrose & RL, followed by Neo Adjuvant chemotherapy was given 
as two (platinum with taxane) or three drug with Platinum, Taxane with 
5-flurouracil (5 FU) every 3 week regimen with Cisplatin and Docetaxel 
as 75 mg/m2 each, 5-FU as 1000 mg/m2. In this group, HRQOL of  
patients of  OCSCC was evaluated before the first cycle of  chem-
otherapy (C0) and patients were evaluated every third week after 
completion of  each cycle of  anticancer drugs (e.g. C1,C2,C3,C4). 
The last evaluation of  HRQOL was done one month after com-
pletion of  the last cycle of  chemotherapy (i.e. C5) [15].
Study instrument
Prior permission was taken from the EORTC group for use of  
their latest (version 3.0) of  general Quality of  Life QLQ-C30 
questionnaire and its Head & Neck Cancer specific QLQ-H&N35 
questionnaires, which is validated in various Indian languages.
EORTC QLQ-C30 Questionnaire (version 3.0): It consists of  
30 questions, out of  30 questions 24 from nine multi-item scales 
presenting various aspects of  HRQOL. It considers five func-
tional scales named physical functioning (PF); social functioning 
(SF); emotional functioning (EF); role functioning (RF); cognitive 
functioning (CF). It includes eight symptom scales named fatigue, 
pain, insomnia, constipation, diarrhea, dyspnoea, appetite loss, nausea and 
vomiting, single scale of  financial difficulty and global health and quality 
of  life [16].
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Site Specific QLQ-H&N35 Questionnaire (version 3.0): It is 
disease-specific for patients having cancer of  head and neck re-
gion. It consists of  35 questions organized in 7 symptoms multi-
item scales having 24 questions related to pain, swallowing, sense 
problem, speech problem, trouble with social eating, trouble with 
social contact and less sexuality and 11 single-item scales describ-
ing different specific concerns of  these head and neck cancer pa-
tients i.e. teeth problem, opening mouth, dry mouth, sticky saliva, 
coughing, felt ill, pain killer, nutritional supplement, feeding tube, 
weight loss and weight gain [16].
Patients were given a HRQOL questionnaire in the vernacular 
language and patient reported outcome of  HRQOL was noted. 
HRQOL ordinal data were scored as per the developer’s manu-
al and scores were linearly transformed in 0 to 100. They were 
grouped according to various symptom scales and functional 
scale [16].
Prospective longitudinal study design
In this observational study, after getting consent, patients’ with 
OCSCC were enrolled in the study from January 2013 to April 
2013, they were divided into CTRT or NACT group as per gen-
eral health status, willingness for surgical treatment, eligibility for 
radiotherapy. Consequenty, patients of  OCSCC were followed up 
from January 2013 to September 2013 to evaluate patient report-
ed quality of  life.
Data collection and follow up
After enrolment in the study, baseline demographic and clinical 
data of  the patients were recorded. HRQOL was evaluated by 
providing EORTC QOL C30 and QOL H&N- C35 question-
naires of  vernacular language to the patients and they were evalu-
ated before starting chemotherapy, after completion of  each cycle 
of  chemotherapy and one month after completion of  full course 
of  treatment. 
All the patients completed the HRQOL questionnaires, in the 
presence of  the study investigator, who had assisted in case of  
difficulties in understanding the questions. To maintain patients' 
compliance, patient or relative was reminded about their next visit 
by telephonic communication.
Statistical Analysis
Overall, HRQOL was scored as per EORTC developer’s instruc-
tions by linearly converting raw EORTC QLQ-C30 scores into 0 
to 100 to facilitate comaprision and readability of  overall score.
For global health status and functioning scales, a score of  100 corresponds 
to a high or best HRQOL. For financial difficulties and the eight symptoms, 
a score of  100 implies maximum difficulty or symptom burden likewise the 
worst HRQOL.
On the whole, sequential changes of  HRQOL scorings were sta-
tistically analyzed using repeated measures ANOVA with post hoc 
Tukey’s comparisons (P < 0.05). Moreover, changes in HRQOL 
score between CTRT and NACT groups were measured by un-
paired t-test (P < 0.05). All stastical analysis was done by using 
GraphPad Instat (version 3) software.
Results 
Sociodemographic characteristics
In the present study, NACT and CTRT group of  patients with 
OCSCC were evaluated for event based HRQOL analysis, (1) 
prior to starting chemotherapy - C0, (2) during active treatment 
period of  chemotherapy- i.e. C1, C2, C3, C4, (3) After completing 
the course of  chemotherapy - C4 for NACT and C6 for CTRT 
group, and (4) one months after completing course of  chemo-
therapy- C5 for NACT and C7 for CTRT group with total sam-
ple of  36 patients by using EORTC QOL C-30 and H&N C-35 
questionnaires.
At the end of  study, patients who were not able to come for fol-
low up at one month after full course of  chemotherapy were 
excluded from analysis. Moreover, effect of  two different treat-
ments named CTRT vs. NACT on HRQOL score was analyzed 
by comparison of  difference of  HRQOL score between NACT 
vs. CTRT after completing the course of  chemotherapy, and 
comparison of  difference of  HRQOL score between NACT vs. 
CTRT one months after completing course of  chemotherapy. 
HRQOL score was grouped into various symptom scales and 
functional scales as per developer’s instructions.
As shown in flow chart of  Figure 1. out of  total 67 enrolled pa-
tients, only 36 (53.73%) could complete the whole HRQOL study 
by follow up at one month after the full course of  chemotherapy. 
On overall comparison of  all the patients, who completed the 
study, all demographic characteristics in both the groups were 
similar and comparable [Table 1].
Figure 1. Flow chart of  enrolment of  patient as per Inclusion and Exclusion criteria.
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On analysis of  site of  involvement of  oral cavity squamous cell 
carcinoma, the most common site was tongue (38.89%) followed 
by buccal mucosa (33.33%), palate (13.89%), alveolus (8.33%), 
retro molar trigone (5.56%) and anterior faucial pillar (2.78%).
  
In looking towards addiction history of  patients, out of  36 pa-
tients, the majority of  patients (80.56%) had one or more addic-
tions like betel nut chewing, smoking tobacco in the form of  bidi 
(one kind of  cigarette) or alcohol consumption.
Majority of  patients reported for the chemotherapy during the 
TNM stage II or III of  OCSCC in both CTRT (33.33% or 
38.89%) and NACT group (27.78% or 50%) [Table 2].
Assessment of  sequential changes in HRQOL score of  
CTRT or NACT group
 
NACT Group: In NACT Group of  patients, there were signifi-
cant differences in majority of  QLQ- H&N35 scales compared to 
baseline on each of  the multiple-item scales: difference in scales 
of  pain (HNPA; P > 0.10), nausea-vomiting (NV; > 0.10), di-
arrhea (DI; P > 0.10), constipation(CO; P = 0.196), insomnia 
(SL; P=0.0794), senses problem (HNSE; P > 0.10), swallowing 
(HNSW; P >0.10), speech (HNSP; P = 0.0628), teeth (HNTE; 
P=0.0617), social eating (HNSO; P > 0.10), social contact (HNSC; 
P=0.054), and sexuality (HNSX; P > 0.10) were not significant.
On analysis of  the 11 single-item scales, there were significant 
differences on the coughing scale (HNCO; P = 0.0002), sticky saliva 
(HNSS; P=0.02), feeling of  illness (HNFI; P < 0.0001), requirement of  
nutritional supplements (HNNU; P = 0.0002), and painkillers (HNPK; 
P = 0.0062) [Figure 2. A-F]. On the other hand, difference in 
score of  opening mouth (HNOM; P = 0.752), requirement of  
feeding tube (HNFE, P > 0.10), dryness of  mouth (HNDR; P > 
0.10), and weight loss (HNWL; P > 0.10) were not significant. On 
the other hand, no differences emerged on the single-item scale 
of  weight gain (HNWG).
On evaluation of  HRQOL by using the core questionnaire 
(QLQ-C30), in NACT group of  patients, on each of  these scales, 
patients had reported poorer baseline functioning at presentation 
of  disease, which persisted till one month after completion of  full 
course of  treatment. Overall, difference in scales on the physical 
functioning (P > 0.10), role functioning (P > 0.10), emotional 
functioning scale (P > 0.10), global quality of  life (P > 0.10), cog-
nitive functioning (P > 0.10), appetite (P > 0.10), and financial 
difficulty (P  > 0.10), and fatigue (P > 0.10) scales were not signifi-
cant, while there was a statistically significant difference in social 
functioning (P = 0.0488) at the end of  one month after completion 
of  full course of  treatment [Figure 2. A-F].
CTRT Group: In CTRT group of  patients, evaluation of  
HRQOL by using the core questionnaire (QLQ- H&N35), can-
cer patients had reported poorer functioning at presentation of  
disease on each of  these scales, which persisted till one month 
after completion of  full course of  treatment likewise scales of  
Pain (HNPA; P > 0.10), senses problem (HNSE; > 0.10), teeth 
(HNTE; P > 0.10), insomnia (SL; P > 0.10), swallowing (HNSW; 
P > 0.10), speech (HNSP; P > 0.10), social eating (HNSO; P > 
0.10), social contact (HNSC; P > 0.10), sexual function (HNSX; P 
> 0.10). On the other hand, development of  complaints of  nau-
sea-vomiting (NV; P > 0.10), diarrhea (DI; P = 0.0813) or consti-
pation (CO; P > 0.10) remained persistent during the course of  
treatment.
On evaluation of  the 11 single-item scales, there was a signifi-
Table 1. Demographic characteristics of  patients of  oral cavity squamous cell carcinoma (N=36)
Criteria CTRT Group (N=18) NACT Group (N=18) Total (N=36)
Age (Years)(Mean±SD) 48±10 47.78±10.94 47.89±10.48
Male 13(36.11%) 13(36.11%) 26(72.22%)
Female 5(13.88%) 5(13.88%) 10(27.78%)
Weight(Kg) (Mean±SD) 49.33±11 47.44±8.16 48.39±9.82
Height(cm) (Mean±SD) 158±11 161.94+10.51 160.19+10.73
BMI (Kg/m2)(Mean±SD) 19.62±3.69 18.07±2.63 18.85±3.25
Married 18(50%) 17(47.22%) 35(97.22%)
Unmarried 0(0.00%) 1(2.77%) 1(2.77%)
CTRT = Concurrent Chemo - Radiation, NACT = Neo-Adjuvant Chemotherapy, SD =  Standard Deviation, 
N = Number of  patients  of  oral  cavity squamous cell carcinoma.
Table 2. TNM stage wise patients' involvement.
TNM Stage of  oral cavity 
squamous cell carcinoma
CTRT(N=18) %(N=18) NACT(N=18) %(N=18)
I 3 16.67 2 11.11
II 6 33.33 5 27.78
III 7 38.89 9 50.00
IV 2 11.11 2 11.11
TNM = Tumor, Nodes and Metastasis, CTRT = Concurrent Chemo - Radiation, NACT = Neo-Adjuvant Chemotherapy;   
N = Number of  patients  of  oral  cavity squamous cell carcinoma
TNM staging as per American Joint Committee on Cancer ( AJCC), Chicago, Illinois 
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cant difference on the opening mouth (HNOM; P = 0.004), sticky 
saliva (HNSS; P = 0.02), dry mouth (HNDR; P < 0.0001), coughing 
(HNCO; P = 0.0002), feeling of  illness (HNFI; P < 0.0001), require-
ment of  nutritional supplements (HNNU; P < 0.0001) and painkillers 
(HNPK; P < 0.0001), while score of  and weight loss (HNWL; P 
> 0.10) was not significant. On the other hand, no differences 
emerged on the single-item scale of  requirement of  feeding tube 
(HNFE) and weight gain (HNWG) [Figure 3. A-H].
On analysis of  HRQOL by using the core questionnaire (QLQ-
C30) in CTRT group of  patients, on each of  these scales, can-
cer patients had reported poorer functioning at presentation of  
disease, which persisted till one month after completion of  full 
course of  treatment. Overall, difference in scales on the pain (PA; 
P > 0.10), physical functioning (PF2; P > 0.10), social function-
ing (SF; P > 0.10), role functioning (RF2; P = 0.0901), emotional 
functioning scale (EF; P > 0.10), global quality of  life (QL2; P 
> 0.10), cognitive functioning (CF; P > 0.10), appetite loss (AP; 
P > 0.10), financial difficulty (FI; P  > 0.10), and fatigue (P = 
0.0663) scales, were non significant, while there was a significant 
improvement in the dyspnoea score (DY; P = 0.0044) at the end of  
one month after completion of  full course of  treatment [Figure 
3. A-H].
Comparison of  HRQOL between CTRT and NACT group
On comparison of  HRQOL score between CTRT and NACT 
group, by looking towards overall treatment outcome analysis as 
compared to baseline (C0), at the end of  a full course of  therapy, 
deterioration of  global health status and development of  dryness 
of  mouth, sticky saliva, sense problem and trouble with social 
eating were more significant in CTRT group compared to NACT 
Figure 2. Event based HRQOL score (%) on completion of  each cycle of  chemotherapy in NACT group (N = 18)
Figure 2 (A) HRQOL score of  Coughing  scale (HNCO) in NACT Group 
(N=18): Significant as compared to baseline (C0) by repeated measure 
ANOVA with  post  hoc Tukey's test; P=0.0002
Figure 2 (D) HRQOL score of  Nutritional supplements (HNNU) in 
NACT Group (N=18): Significant as compared to baseline (C0) by re-
peated measure ANOVA with  post  hoc Tukey's test; P=0.0002
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Figure 2 (B) HRQOL score of  Sticky  salvia (HNSS) in NACT Group 
(N=18): Significant as compared to baseline (C0) by repeated measure 
ANOVA with  post  hoc Tukey's test; P=0.02
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Figure 2 (E) HRQOL score of  Painkillers (HNPK) in NACT Group 
(N=18): Significant as compared to baseline (C0) by repeated measure 
ANOVA with  post  hoc Tukey's test; P=0.0062
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Figure 2 (C) HRQOL score of  Feeling illness (HNFI) in NACT Group 
(N=18): Significant as compared to baseline (C0) by repeated measure 
ANOVA with  post  hoc Tukey's test; P<0.0001
C0 C1 C2 C3 C5
2.97
1.89
2.43
3.32 
2.24 
2.78
3.50 
2.42 
2.96
4.05
2.97
3.51
C4
4.66
3.58
4.12
5.10
4.02
4.56
Figure 2 (F) HRQOL score of  Social Functioning (HNSO) in NACT 
Group (N=18): Significant as compared to baseline (C0) by repeated 
measure ANOVA with  post  hoc Tukey's test; P=0.0488
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group (P < 0.05) [Figure 4].
Discussion
On the whole, many studies dealing with QoL in head and neck 
cancer have been based on heterogeneous groups of  patients with 
respect to different site and stage of  tumour. Only a few prospec-
tive studies have focused on a specific anatomic site and type like 
oral cavity squamous cell carcinoma [17].
This study is one of  the first to examine the HRQOL by using 
the new EORTC QLQ-H&N35 module in Indian patients with 
Figure 3. Event based HRQOL score (%) on completion of  each cycle of  chemotherapy in CTRT group.
Figure 3 (A) HRQOL score of  Opening of  Mouth (HNOM) in CTRT 
Group (N=18): Significant as compared to baseline (C0) by repeated 
measure ANOVA with  post  hoc Tukey's test; P=0.004
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Figure 3 (E) HRQOL score of  Feeling of  illness (HNFI) in CTRT Group 
(N=18): Significant as compared to baseline (C0) by repeated measure 
ANOVA with  post  hoc Tukey's test; P<0.0001
Figure 3 (B) HRQOL score of  Sticky saliva (HNSS) in CTRT Group 
(N=18): Significant as compared to baseline (C0) by repeated measure 
ANOVA with  post  hoc Tukey's test; P=0.02
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Figure 3 (F) HRQOL score of  Nutritional supplements (HNNU) in 
CTRT Group (N=18): Significant as compared to baseline (C0) by re-
peated measure ANOVA with  post  hoc Tukey's test; P<0.0001
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Figure 3 (C) HRQOL score of  Dryness of  Mouth (HNDR) in CTRT 
Group (N=18): Significant as compared to baseline (C0) by repeated 
measure ANOVA with  post  hoc Tukey's test; P=0.0001
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
-10.00
80.00
Mean+SEM
Mean
Mean-SEM
C0 C1 C2 C3 C5C4 C6 C7 0.00
20.00
40.00
60.00
80.00
100.00
120.00
Figure 3 (G) HRQOL score of  Painkillers (HNPK) in CTRT Group 
(N=18): Significant as compared to baseline (C0) by repeated measure 
ANOVA with  post  hoc Tukey's test; P<0.0001
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Figure 3 (D) HRQOL score of  Coughing (HNCO) in CTRT Group 
(N=18): Significant as compared to baseline (C0) by repeated measure 
ANOVA with  post  hoc Tukey's test; P=0.0002
Figure 3 (H) HRQOL score of  Dyspnoea (DY) in CTRT Group 
(N=18): Significant as compared to baseline (C0) by repeated measure 
ANOVA with  post  hoc Tukey's test; P=0.0044
0.00
1.00
2.00
3.00
4.00
5.00
-1.00
Mean+SEM
Mean
Mean-SEM
C0 C1 C2 C3 C5C4 C6 C7
0.58
-0.58
0.00
1.81
0.66
1.23
1.96
0.80
1.38
3.05
1.89
2.47
3.17
2.01
2.59
3.61
2.45
3.03
4.13
2.97
3.55
4.28
3.13
3.70
-0.50
0.00
-1.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
Mean+SEM
Mean
Mean-SEM
C0 C1 C2 C3 C5C4 C6 C7
3.93
2.13
3.03
3.93
2.13
3.03
3.37
1.57
2.47
2.69
0.89
1.79
2.58
0.78
1.68
2.14
0.33
1.23
1.72
-0.08
0.82
1.35
-0.45
0.45
HRQOL score is expressed as Mean ± SEM in percentage out of  100
Abbreviations: HRQOL = Health related  Quality of   Life, CTRT = Concurent Chemo-Radiation, SEM = Standard Error of  Mean, 
ANOVA = Analysis of  variance, N= Number of  patients, C0 = Baseline HRQOL before starting treatment, C1 = HRQOL after First 
cycle of  chemotherapy, C2 =  HRQOL after Second cycle of  chemotherapy, C3 = HRQOL after Third cycle of  chemotherapy, C4 = 
HRQOL after Fourth cycle of  chemotherapy, C5 = HRQOL after Fifth cycle of  chemotherapy, C6 = HRQOL after Sixth cycle of  
chemotherapy, C7 = HRQOL at 1 month after Full cource(sixth cycle) of  chemotherapy.
Mistry CB, Rana DS, Batra V (2015) Evaluation of  Health Related Quality of  Life in Patient with Oral Cavity Squamous Cell Carcinoma Receiving Chemotherapy. Int J Clin Pharma-
col Toxicol, 4(2) 161-168. 167
www.scidoc.org/IJCPT.php
Oral cavity squamous cell carcinoma. As instruments of  EORTC 
questionnaires showed good internal consistency compared to ex-
isting alternative tools, their instrument is preferred and selected 
over other available tools [18]. Moreover, reliability in the form 
of  external and internal validity has already been established by 
various previous studies, so it gives consistent result on follow up 
[19]. 
In this observational study, all enrolled patients were inhabitant 
of  western India. And the majority of  patients of  OCSCC pre-
sented during the fourth or fifth decade of  life, which is similar to 
the findings that observed by Shenoi P et al. and Sankaranarayana 
et al [7, 20]. 
Out of  all patients of  the OCSCC, majority of  the patients were 
male and they were farmer by occupation, which is aligned with 
Indian demographic data suggestive of  male predominance for 
development of  oral cancer [21]. In addition to that, more than 
half  of  the patients with OCSCC presented during advanced 
TNM stage of  the disease, which is similar to Indian patients’ 
presentation at outpatient department [22].
According to previous Indian study, oral or mouth cancer most 
commonly involves the tongue, which may also occur on the floor 
of  the mouth, cheek lining, gingiva (gums), lips, palate (roof  of  
the mouth), maxilla or mandible. Similar findings were observed 
in this study as majority of  patients presented with OCSCC of  
anterior 2/3rd of  tongue, followed by buccal mucosa, palate, al-
veolus, retro molar trigone and anterior faucial pillar [23]. 
On event based follow up for analysis of  HRQOL, development 
of  complaints of  nausea, vomiting, feeling of  illness, weight loss, 
fatigue, impaired socialization (decrease in involvement of  social 
activity or eating in the presence of  relatives), requirement of  nu-
tritional supplements and painkillers were progressive compared 
to baseline in both the treatment groups, which were related to 
disease itself  or adverse reaction due to chemotherapy or radio-
therapy in both the CTRT and NACT groups.
As compared to NACT group, patients of  CTRT group had de-
veloped more deterioration in global health status, dryness of  
mouth, sticky saliva, persistent coughing, and sensory problems 
after complete course of  chemotherapy treatment, which persist-
ed even at one month follow up. These findings were similar to 
Brazilian study, which showed that worsening of  HRQOL after 
diagnosis and treatment was more among patients treated with 
radiotherapy [24].
In CTRT group, the opening of  mouth and chewing function 
was compromised at presentation and further deteriorated during 
follow up study. Likewise, many authors previously stressed that 
opening of  mouth was compromised due to submucous fibrosis, 
mandibular reconstruction by bony free flaps, and osteo-integrat-
ed dental rehabilitation. In fact, dental status and prosthetic re-
habilitation before radiation treatment play only a partial role in 
chewing ability. Moreover, in advanced cancers of  the retromolar 
trigone extending to the tonsillar region, resection of  the ptery-
goid muscles always leads to heavy trismus that, in many cases, is 
irreversible and extremely invalidating [25].
On sequential evaluation of  HRQOL score, there was deteriora-
tion in most of  the HRQOL score, while in CTRT group; there 
was improvement of  dyspnoea on overall analysis. HRQOL score 
of  development of  dyspnoea had decreased compared to base-
line, which may be attributed to shrinkage of  tumour, decreased 
secretions and clearance of  blockage of  upper respiratory tract by 
Concurrent Chemoradiation.
Overall, more deterioration of  Global Quality of  Life in CTRT 
group as compared to NACT group can be due to development 
of  mucositis which is characterised by dryness of  mouth, sticky 
saliva, sense problem and trouble with social eating in CTRT 
group. In this perspective, few authors of  previous studies have 
focused on residual tongue mobility, a factor which in terms of  
functional outcome of  eating disability is much more crucial than 
the amount of  preserved tongue [25]. 
In short, statistical significant score of  HRQOL need to be corre-
lated with clinical scenario. However, many previous studies failed 
to identify a statistically significant relationship between clinical 
parameters and functional outcomes, probably on account of  the 
cross-sectional design and grouping of  different head and neck 
sites and treatment modalities [25].
Figure 4. Comparison of  HRQOL difference between  CTRT and NACT group at the end of  treatment.
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Strength and weakness of  this study
This study was focused on oral cavity, so a study on a single region 
can give more robust result compared to generalised study includ-
ing more number of  sites of  head and neck cancer. Moreover, 
evaluation of  HRQOL in vernacular language was able to make 
patients aware about early signs of  progression of  cancer and ad-
verse drug reactions which can help them to approach healthcare 
facility on early basis.       
On the other hand, patients with advanced stage of  cancer could 
not survive longer or lost to follow up due to multiple reasons, so 
their HRQOL could not be evaluated. Consequently, this study 
was limited by the small sample of  patients completing question-
naires at one month after full course of  chemotherapy, which can 
be extended for more duration with involvement of  multiple cen-
tres.
Conclusion
This study demonstrated that in patients of  oral cavity squamous 
cell carcinoma, overall baseline HRQOL remained poor, which 
further deteriorated more in patients receiving CTRT as com-
pared to that of  NACT group.
Overall, more deterioration of  Global Quality of  Life in Con-
current Chemo-Radiation (CTRT) group as compared to Neo-
Adjuvant Chemotherapy (NACT) group was detected due to sig-
nificant development of  dryness of  mouth, sticky saliva, sense 
problem and trouble with social eating in CTRT group of  pa-
tients.
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